Development of Second-Generation CDK2 Inhibitors for the Prevention of Cisplatin-Induced Hearing Loss.
Development of Second-Generation CDK2 Inhibitors for the Prevention of Cisplatin-Induced Hearing Loss.
复制标题
DOI:
10.1021/acs.jmedchem.8b00669
复制
发表时间:
2018-09-13
影响因子:
7.3
通讯作者:
Zuo J
中科院分区:
文献类型:
--
作者:
Hazlitt RA;Teitz T;Bonga JD;Fang J;Diao S;Iconaru L;Yang L;Goktug AN;Currier DG;Chen T;Rankovic Z;Min J;Zuo J
There are currently no FDA-approved therapies to prevent the hearing loss associated with the usage of cisplatin in chemotherapeutic regimens. We recently demonstrated that the pharmacologic inhibition with kenpaullone or genetic deletion of CDK2 preserved hearing function in animal models treated with cisplatin, which suggests that CDK2 is a promising therapeutic target to prevent cisplatin-induced ototoxicity. In this study, we identified two lead compounds, AT7519 and AZD5438, from a focused library screen of 187 CDK2 inhibitors, performed in an immortalized cell line derived from neonatal mouse cochleae treated with cisplatin. Moreover, we screened 36 analogs of AT7519 and identified analog 7, which exhibited an improved therapeutic index. When delivered locally, analog 7 and AZD5438 both provided significant protection against cisplatin-induced ototoxicity in mice. Thus, we have identified two additional compounds that prevent cisplatin-induced ototoxicity in vivo, and provided further evidence that CDK2 is a druggable target for treating cisplatin-induced ototoxicity.
登录
查看更多内容
影响因子:
6
作者:
Ciarimboli, Giuliano;Deuster, Dirk;Schlatter, Eberhard
通讯作者:
Schlatter, Eberhard
影响因子:
2.8
作者:
Park, Hee-Je;Kim, Hyung-Jin;Park, Sung-Joo
通讯作者:
Park, Sung-Joo
影响因子:
3.9
作者:
Sooriyaarachchi, Melani;Gailer, Jurgen;George, Graham N.
通讯作者:
George, Graham N.
影响因子:
7.3
作者:
Wyatt, Paul G.;Woodhead, Andrew J.;Woolford, Alison J. -A.
通讯作者:
Woolford, Alison J. -A.
DOI:
10.1073/pnas.1424313112
发表时间:
2015-04-21
影响因子:
11.1
作者:
Pabla, Navjotsingh;Gibson, Alice A.;Sparreboom, Alex
通讯作者:
Sparreboom, Alex